In8Bio (INAB) Accounts Payables (2020 - 2026)
In8Bio (INAB) posted Accounts Payables of $449000.0 for Q1 2026, up 45.31% sequentially from $309000.0 in Q4 2025, and down 21.91% YoY from $575000.0 in Q1 2025.
In8Bio (INAB) Accounts Payables (2020 - 2026) Analysis & Trends
In8Bio has reported Accounts Payables for 7 years, with the latest figure at $449000.0 in Q1 2026.
- Quarterly Accounts Payables fell 21.91% year-over-year to $449000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $449000.0 (down 21.91% YoY) and the FY2025 annual result came in at $309000.0, down 20.57% from the prior year.
- Accounts Payables improved to $449000.0 in Q1 2026 per INAB's latest filing, from $309000.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $2.1 million in Q4 2022 and troughed at $204000.0 in Q3 2025.
- A 5-year average of $790750.0 and a median of $666500.0 in 2023 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2025: Accounts Payables jumped 429.37% in 2022, then slumped 82.06% in 2025.
- Over 5 years, Accounts Payables stood at $2.1 million in 2022, then slumped by 55.81% to $924000.0 in 2023, then plunged by 57.9% to $389000.0 in 2024, then fell by 20.57% to $309000.0 in 2025, then jumped by 45.31% to $449000.0 in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $449000.0, $309000.0, and $204000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | In8Bio | 22.97 Mn | 22.97 Mn | - | 444,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 444,000.00 |
| Mar 31, 2026 | 449,000.00 |
| Dec 31, 2025 | 309,000.00 |
| Sep 30, 2025 | 204,000.00 |
| Jun 30, 2025 | 379,000.00 |
| Mar 31, 2025 | 575,000.00 |
| Dec 31, 2024 | 389,000.00 |
| Sep 30, 2024 | 1.14 Mn |
| Jun 30, 2024 | 1.44 Mn |
| Dec 31, 2023 | 924,000.00 |
| Sep 30, 2023 | 748,000.00 |
| Jun 30, 2023 | 585,000.00 |
| Mar 31, 2023 | 870,000.00 |
| Dec 31, 2022 | 2.09 Mn |
| Sep 30, 2022 | 1.11 Mn |
| Jun 30, 2022 | 887,000.00 |
| Mar 31, 2022 | 553,000.00 |
| Dec 31, 2021 | 395,000.00 |
| Sep 30, 2021 | 692,000.00 |
| Jun 30, 2021 | 462,000.00 |